BSE filing, NSE: NORRIS. Summary written from the filing by ALFA Finder's alert engine.
Norris Medicines Ltd: key numbers
- Share price
- ₹14.62
- Market cap
- ₹14.62 Cr
- Revenue (annual)
- ₹8.13 Cr
- Net profit (annual)
- ₹-0.28 Cr
- P/E (TTM)
- -39.8×Sector 46.1×
- Promoter holding
- 34.01%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Norris Medicines Ltd
All →Norris Medicines Annual General Meeting
Norris Medicines Limited held its 35th Annual General Meeting on September 29, 2026, where members transacted various ordinary and special business items.
Norris Medicines Annual Report
Norris Medicines Limited has filed its 35th Annual Report for the financial year 2025-26, including the notice of its upcoming Annual General Meeting.
Norris Medicines Annual General Meeting
Norris Medicines approved the Directors' Report, Annual Report, and convening of the 35th Annual General Meeting for September 29, 2026.
Norris Medicines Q1 FY27 Results: Net Loss of ₹0.4 Cr, Loss Widens
Norris Medicines Ltd reported revenue from operations of ₹0.9 Cr (-40.0% YoY) and a net loss of ₹0.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.4 Cr
Norris Medicines Board Meeting Date
Norris Medicines Limited has scheduled a board meeting for August 14, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.
Norris Medicines Management Change
Norris Medicines Limited has appointed Mr. Iqubal Ismail Patel as the Chief Financial Officer and Key Managerial Personnel, effective July 30, 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.